PROVIDENCE, R.I. (April 20, 2026) — University Gastroenterology (UGI), a leading provider of digestive health care in Rhode Island and Southeastern Massachusetts, has launched a series of clinical trials studying the use of GLP-1 medications for patients with fatty liver disease (MASH), inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS).
These studies offer eligible participants access to therapies at no cost, with many participants also receiving compensation for their time. Some of these therapies are FDA-approved, while others are investigational, allowing researchers to evaluate emerging treatment options. GLP-1 medications have gained national attention for their use in metabolic conditions, and researchers are now exploring their potential role in treating complex gastrointestinal diseases that affect millions of Americans.
Addressing Common and Challenging Conditions
The clinical trials focus on conditions that significantly impact quality of life:
- Fatty Liver Disease (MASH)
- Inflammatory Bowel Disease (IBD)
- Irritable Bowel Syndrome (IBS)
By participating in these studies, patients may gain access to new approaches that are not yet widely available.
No-Cost Participation and Compensation Available
Qualified participants may receive:
- Study-related medications at no cost
- Access to specialized care and monitoring
- Compensation for time and participation
Advancing Research Close to Home
University Gastroenterology is recognized for its commitment to clinical research and innovation, offering patients in the region access to advanced therapies typically found only at major academic centers.
How to Participate
Individuals interested in learning more about eligibility can visit: https://www.universitygi.com/ongoing-trials/ or call 401-227-8393 for more information.
Media Opportunities
University Gastroenterology is available for interviews, patient stories, and expert commentary on GLP-1 medications and digestive health.